Yili Chuanning Biotechnology Co. Ltd. A301301
▲ PositiveCapitalrelevance
First-half net profit of 278 million yuan and synthetic biology revenue up 221% indicate strong financial performance.
Impact on stocks 1
Others▲ · 1 stocks
Yili Chuanning Biotechnology Co. Ltd. ATheme Impact 1
Off-coverage companies
Related news
▲
Biological Computing Market to Reach $2.9 Billion by 2026
The global biological computing market is projected to grow from $2.21 billion in 2025 to $2.90 billion in 2026, a compound annual growth rate of 31.2%, according to a new report from ResearchAndMarkets.com. The market is forecast to reach $8.64 billion by 2030, expanding at a CAGR of 31.4% from 2026. Growth is driven by advances in DNA sequencing, synthetic biology, and bioinformatics, as well as demand for energy-efficient computing and personalized medicine. Key trends include DNA-based computing, synthetic biology-driven systems, and hybrid biological-digital platforms. Notable developments include FinalSpark's Neuroplatform for cloud-based biocomputing with human brain organoids and a partnership between VERSES Technologies and Cortical Labs to integrate AI with living neurons. North America led the market in 2025, while Asia-Pacific is expected to grow fastest. The report profiles major players such as Thermo Fisher Scientific, Illumina, and Ginkgo Bioworks.
5
Cathay Biotech first-half net profit 372 million yuan, up 20.75% year on year
Cathay Biotech disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 1.9 billion yuan, up 13.73% year on year, and net profit attributable to shareholders of the listed company of 372 million yuan, up 20.75% year on year. The profit growth was mainly driven by continued volume expansion of long-chain dibasic acids and revenue contribution from new product sales. During the reporting period, bio-based sebacic acid and bio-based piperidine continued to be introduced to the market, bio-based azelaic acid entered the customer sampling stage, and long-chain polyamide modified products achieved large-scale sales. The company also led an investment in and increased its stake in the AI protein design company MoleculeMind, and currently holds about 17.43% of its shares, making it the largest external shareholder. At the same time, its self-built high-throughput research and development platform has entered the commissioning stage.
▲
Cibus pushes Latin America rice launch to 2028, sees $20M-$40M biofragrance opportunity
Cibus updated its Latin America rice launch timing to 2028 while outlining a potential $20 million to $40 million annual revenue opportunity from biofragrance partnerships. CEO Craig Wichner, on his first earnings call, emphasized scaling revenue and capital discipline, while CFO Carlo Broos reported cash and equivalents of $20.4 million as of June 30, 2026, sufficient into early Q1 2027. Q2 revenue was $1 million, with six-month revenue up 35% to $2.7 million, and net loss was $22.1 million, or $0.29 per share. Management expects royalties to start flowing in 2028 and build through 2029, and reiterated expectations for additional biofragrance scale-up orders in the second half of 2026.